Shots:
- Mabwell has dosed the first patient with 7MW4911 in a P- I/II study in the US for the treatment of advanced colorectal cancer & other advanced GI tumors
- Preclinical studies showed that 7MW4911 delivered potent antitumor activity across CDX/PDX GI tumor models & outperformed MMAE/DXd-based ADCs in multidrug-resistant settings. It also reversed tumor progression after prior ADC treatment, with findings published at AACR 2025 & in Cell Reports Medicine (July 2025)
- 7MW4911 is a CDH17-targeting ADC from Mabwell’s IDDC platform, combining an internalizing mAb, a highly stable cleavable linker, & the MF-6 DNA topoisomerase I inhibitor payload designed to overcome multidrug resistance
Ref: PRnewswire | Image: Mabwell | Press Release
Related News: Mabwell’s Adalimumab Injection (Biosimilar, Humira) Granted Marketing Approval in Indonesia
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
